Inside the Race to Treat the Deadliest Brain Vascular Malformation in Newborns

Deep in the center of the brain, a rare vascular anomaly can turn a newborn’s first days of life into a fight against overwhelming heart failure. Vein of Galen malformation, or VOGM, is a complex cerebrovascular disorder in which arteries connect directly to a primitive embryonic vein, bypassing the capillary network that normally slows and distributes cerebral blood flow. The resulting high-flow shunt dramatically increases cardiac preload and can lead to high-output heart failure, pulmonary overflow, systemic steal, and rapid deterioration after birth. A new review published in Frontiers in Pediatrics synthesizes evidence and expert perspectives presented at the II International Meeting on Vein of Galen Malformation in Newborns and Children, held in Camogli, Italy, in October 2025, and maps out how the field is rapidly evolving from survival-focused treatment toward individualized, multidisciplinary care extending from fetal diagnosis through childhood and adulthood.

The historical trajectory of VOGM management illustrates how far the field has come. Early observations of vascular anomalies date back to the eighteenth century, but the distinct nature of VOGM was only recognized in the twentieth century. The first published case appeared in a detailed and illustrated article by Jaeger in 1946, and the first successful treatment in 1949 involved experimental ligation of the carotid artery. A full understanding of the anomaly’s developmental basis emerged later, thanks to publications by Raybaud and colleagues, who established that the lesion incorporates the median prosencephalic vein of Markowski, confirming its choroidal nature and timing of formation. A critical turning point was the shift from surgical to endovascular treatment, with embolization techniques introduced in the late twentieth century enabling targeted, minimally invasive interventions. Contemporary approaches now include transarterial, transvenous, hybrid, and even fetal techniques, reflecting the rapid evolution of the field.

Perinatal management has become a major focus of recent research, where early diagnosis and risk stratification are critical determinants of outcome. Advances in prenatal imaging, particularly ultrasound and fetal magnetic resonance imaging, have enabled earlier detection of VOGM and more detailed assessment of associated cardiovascular and neurological involvement. Despite these advances, predicting perinatal clinical courses remains challenging. Multiple prenatal markers such as cardiomegaly, tricuspid regurgitation, and abnormal flow patterns have been proposed, but no single parameter reliably predicts prognosis. Prenatal neuroradiological factors, such as straight-sinus or falcine-sinus mediolateral diameter or the presence of pseudofeeders, represent potential markers for high-risk neonatal presentation and worse outcomes. A particularly important topic is the identification of the high-risk subgroup of newborns who require early neonatal intervention, often within the first week of life, and who tend to have significantly poorer outcomes. Multiparametric models integrating cardiovascular, anatomical, and neurological data have been proposed as a promising tool for stratifying postnatal clinical courses.

One of the most important recent developments is the emergence of fetal embolization as a potential therapeutic strategy. Early single-center experience demonstrates technical feasibility and suggests the potential for improved outcomes in carefully selected high-risk fetuses, with substantial reduction in cardiac output observed. However, the small sample size, absence of a concurrent control group, short follow-up, and substantial risk of unscheduled delivery preclude conclusions regarding efficacy. Complementary preclinical work in animal models demonstrated the feasibility of transcardiac fetal arterial access for embolization, opening a new potential approach for prenatal therapy. These findings suggest that fetal intervention may represent an additional paradigm shift in the management of severe VOGM.

The cardiovascular pathophysiology of VOGM imposes a significant hemodynamic burden on the fetus and newborn due to a large intracranial arteriovenous shunt that increases cardiac preload and can lead to high-output heart failure. During fetal development, the low-resistance and high-capacitance uteroplacental circulation exerts a protective role for the fetus. However, after birth, the sudden loss of placental circulation and lowering of pulmonary vasculature resistance result in dramatic hemodynamic imbalance, including severe pulmonary overflow, systemic steal, and rapid progression to cardiac failure. Neonatal management has evolved toward a pathophysiology-driven approach, with primary goals including stabilizing cardiac function, optimizing systemic perfusion, and preparing the patient for endovascular intervention. Strategies involve tailored ventilation, targeted use of inotropic and vasoactive agents, and avoidance of therapies that may exacerbate pulmonary overcirculation, such as pulmonary vasodilators including inhaled nitric oxide. Ductal patency active management via prostaglandin E1 has been specifically reported for patients with refractory pulmonary hypertension.

Neuroimaging plays a pivotal role in all stages of VOGM management, from prenatal diagnosis to treatment planning and follow-up. The meeting highlighted the transition from purely anatomical imaging to a more comprehensive, multiparametric and prognostic approach. Modern MRI protocols incorporate structural imaging, diffusion-weighted imaging, angiography, and advanced flow analysis techniques such as 4D flow MRI and 4D MR angiography based on pseudocontinuous arterial spin labeling. Quantitative flow measurements demonstrated early and delayed reductions in shunt flow following embolization. While larger VOGMs are often associated with several venous features, absolute volume alone does not reliably predict outcomes, supporting the hypothesis that VOGM size is closely linked to venous hemodynamics rather than acting as an isolated prognostic marker. Instead, a volume-to-brain ratio corrected for age at MRI may represent a promising feature in predicting survival in pre-embolization cases. The mediolateral diameter of the straight sinus or falcine sinus has emerged as a strong morphologic prognostic metric, and a falcine sinus width of at least seven millimeters was used as an eligibility criterion in the initial fetal embolization protocol.

Genetic and molecular insights have transformed understanding of the disease biology. Brain arteriovenous malformations are now recognized as mutation-driven vascular diseases in which somatic activation of developmental pathways bypasses normal vascular stabilization. Pathogenic variants in RASA1 and EPHB4 have been identified in both sporadic and familial cases, linking VOGM to broader vascular disorders such as capillary malformation-arteriovenous malformation syndrome. These genes converge on Ras/MAPK signaling pathways, influencing angiogenesis and vascular remodeling. The convergence of genomic discovery, single-cell atlasing, and translational modeling provides a rationale for targeted therapies, including MEK and KRAS pathway inhibitors. Groundbreaking translational research on zebrafish models reveals that VOGM may result from defective signaling pathways with faulty shear-stress mechanosensing, causing failure of vascular fusion. Zebrafish mutated for either RASA1 or EPHB4 show similar vascular anomalies and increased cardiac output as VOGM patients, and pharmacological targeting using ERK inhibitors and PI3K activators was successful in restoring proper vessel fusion, suggesting potential pharmacological therapeutic applications. Current research is also evaluating the feasibility of endoluminal biopsy during VOGM embolization for isolating endothelial somatic variants and profiling candidate second-hit mutations.

Accurate risk stratification remains essential for guiding treatment decisions and improving outcomes. The historical Bicêtre score has long been used to assess neonatal severity and determine the timing of intervention, but advances in clinical care have exposed its limitations. The score was developed in an era when severe neonatal presentation was frequently considered a marker of treatment futility, whereas advances in neonatal intensive care, neurointerventional techniques, and multidisciplinary management have expanded the population that can be successfully treated. Importantly, the Bicêtre score provides a predominantly clinical assessment of cardiac, respiratory, neurological, renal, and hepatic dysfunction but does not directly incorporate cerebral parenchymal injury, VOGM architecture and dynamics, or quantitative hemodynamic and perfusion parameters. Several contemporary series have therefore questioned the use of rigid Bicêtre thresholds for determining treatment versus palliation, particularly in neonates with potentially reversible systemic dysfunction. The goal is to develop a tailored and dynamic risk-stratification system that captures the clinical complexity of modern VOGM management, with prospective multicenter validation necessary before such tools can be incorporated into routine decision-making.

Endovascular treatment remains the cornerstone of VOGM management. The endovascular approach can be performed through arterial, venous, or combined routes, depending on the angioarchitecture of the lesion, with the ultimate goal being durable angiographic disconnection of the pathological arteriovenous shunts, often achieved through staged embolization while preserving normal deep venous drainage. Transarterial embolization is generally safer and preferred initially, especially for mural-type lesions with limited feeders, while transvenous embolization may be necessary for complex choroidal lesions or cases with numerous arterial feeders, although it carries higher risks due to potential compromise of critical venous drainage pathways. Failure to recognize critical venous connections can result in catastrophic complications, underscoring the need for meticulous pre-procedural imaging and planning. Experts also reviewed the limitations of existing endovascular devices and proposed improvements, including shorter and more flexible catheters and microwires suitable for smaller pediatric vessels, miniaturized systems, improved liquid embolic agents with better flow control, and novel transvenous devices capable of gradually reducing venous outflow through controlled thrombosis. Jugular bulb stenosis emerged as a key determinant of outcome, and management ranges from observation and embolization of the primary lesion to angioplasty or stenting in selected severe cases. For particularly challenging patients with bilateral internal jugular vein occlusion, hybrid surgical-endovascular techniques involving direct venous sinus access have shown promising results.

Historically, outcome data for neonates and children with VOGM has focused on mortality or overall morbidity, with relatively few studies reporting detailed neurologic outcomes. In general, favorable outcome rates range from 50 percent in older neonatal cohorts to 70 percent in more recent studies, with best results in cases of treatment after the neonatal period. Approximately 10 percent of survivors are diagnosed with epilepsy and or autism spectrum disorder. Although many patients achieve favorable overall outcomes, a substantial proportion still experiences long-term neurodevelopmental challenges, including cognitive deficits, processing speed impairment, and behavioral and emotional issues. Even patients classified as having good outcomes may exhibit subtle but clinically significant difficulties in executive functions or mental health. Given the rarity and clinical heterogeneity of VOGM, large multicenter datasets are critical for advancing understanding of its epidemiology, clinical course, treatment approaches, and long-term outcomes. Within the framework of the International Pediatric Stroke Study, a specific VOGM registry was established in May 2024 to collect detailed clinical, imaging, treatment, and outcome data from affected patients. Comprehensive care also requires structured support for patients and families, with dedicated multidisciplinary VOGM teams including psychologists and case managers providing coordinated expertise across specialties. Best practices emphasize early, developmentally appropriate disclosure of the diagnosis to children, supported by structured communication strategies and tailored educational materials, as open and age-appropriate communication promotes better psychological adaptation, greater illness understanding, and more favorable emotional and behavioral outcomes over time. Together, these initiatives reflect a rapidly evolving field that is successfully moving beyond simple survival toward a comprehensive focus on long-term health, neuropsychological assessment, and quality of life.

Subject of Research: Vein of Galen malformation in newborns and children: contemporary advances and future directions

Article Title: Vein of Galen malformation in newborns and children: contemporary advances and future directions

Article References: Buratti, S., Rossi, A., & Orbach, D. B. (2026). Vein of Galen malformation in newborns and children: contemporary advances and future directions. Frontiers in Pediatrics, 14, Article 1996440. https://doi.org/10.3389/fped.2026.1996440

Image Credits: AI Generated

DOI: 10.3389/fped.2026.1996440

Keywords: vein of Galen malformation, cerebrovascular disorder, fetal intervention, endovascular therapy, neuroimaging, genetics, neurodevelopmental outcomes, pediatric critical care, Vein, Galen, malformation, newborns